These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33979777)

  • 1. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
    Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
    Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
    Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
    Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.
    Walter MA; Nesti C; Spanjol M; Kollár A; Bütikofer L; Gloy VL; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Kaderli RM
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013700. PubMed ID: 34822169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
    Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
    JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
    Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
    Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of neuroendocrine tumours to somatostatin analogs.
    Angelousi A; Koumarianou A; Chatzellis E; Kaltsas G
    Expert Rev Endocrinol Metab; 2023 Jan; 18(1):33-52. PubMed ID: 36651768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
    Merola E; Panzuto F; Delle Fave G
    Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.